首页> 外文期刊>Metabolism: Clinical and Experimental >Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
【24h】

Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.

机译:在健康受试者以及患有糖尿病和慢性肾功能衰竭的患者中评估具有血清可的松/皮质醇比率的全身性11β-羟类固醇脱氢酶。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

11beta-hydroxysteroid dehydrogenase (11beta-HSD), an enzyme regulating mineralocorticoid like action of glucocorticoid, oxidizes active cortisol to inactive cortisone. Impaired activity of this enzyme is associated with apparent mineralocorticoid excess (AME) syndrome and is characterized by hypertension and hypokalemia. Recent investigations suggest the presence of hypertensive subjects with low activity of 11beta-HSD. The blood concentration ratio of cortisone/cortisol reflects the overall conversion of cortisol to cortisone and may be an index to assess the systemic activity of 11beta-HSD. We evaluated the peripheral blood concentration ratio of cortisone/cortisol as a possible marker to identify subjects with hypertension thought to represent impaired 11beta-HSD activity. We compared this ratio in healthy subjects and patients with diabetes mellitus (DM) or chronic renal failure (CRF). Peripheral blood samples were collected from 69 healthy subjects, 44 DM, and 36 CRF patients in the morning (9:00 to 11:00 AM). Twenty-six DM patients (59%) and 32 CRF patients (89%) met the criteria for having hypertension. Serum cortisol and cortisone concentrations were determined by high performance liquid chromatography (HPLC). All values for serum cortisone and cortisol levels were within the normal range. Serum cortisone/cortisol ratio in the healthy subjects was distributed with a range of 0.113 to 0.494 (median, 0.243). Compared with healthy subjects, DM and CRF patients had significantly low (P <.01) serum cortisone/cortisol levels (median, 0.188 [range, 0.092 to 0.313] in DM and 0.088 [range, 0.031 to 0.140] in CRF). Bimodal distribution of cortisone/cortisol, found in DM patients with hypertension, represented high- and low-ratio groups around the border of the ratio 0.2. Kidney function, DM duration, and complications varied between the high- and low-ratio groups. The low ratio group (<0.2), whose 11beta-HSD activity was considered low, had an increase in blood urea nitrogen (BUN) levels and experienced nephropathy, neuropathy, retinopathy, and prolonged DM duration when compared with the group with a ratio greater than 0.2. The data suggest that the serum cortisone/cortisol ratio reflects the change in 11beta-HSD activity and is dependent kidney function. This is a possible marker to evaluate glucocorticoid excess hypertension observed in DM and CRF patients. Copyright 2001 by W.B. Saunders Company
机译:11beta-羟类固醇脱氢酶(11beta-HSD)是一种调节盐皮质激素样糖皮质激素作用的酶,可将活性皮质醇氧化为非活性可的松。该酶活性降低与明显的盐皮质激素过量(AME)综合征有关,并以高血压和低血钾为特征。最近的研究表明存在11beta-HSD活性低的高血压受试者。可的松/皮质醇的血药浓度比反映了皮质醇向可的松的总体转化率,可能是评估11beta-HSD全身活性的指标。我们评估了可的松/皮质醇的外周血浓度比作为可能的标志物,以鉴定被认为代表受损的11beta-HSD活性的高血压患者。我们比较了健康受试者和糖尿病(DM)或慢性肾功能衰竭(CRF)患者的这一比率。早晨(9:00至11:00 AM)从69位健康受试者,44位DM和36位CRF患者中采集外周血样本。 26名DM患者(59%)和32名CRF患者(89%)符合高血压标准。通过高效液相色谱(HPLC)测定血清皮质醇和可的松浓度。血清可的松和皮质醇水平的所有值均在正常范围内。健康受试者的血清可的松/皮质醇比值分布范围为0.113至0.494(中位数为0.243)。与健康受试者相比,DM和CRF患者的血清可的松/皮质醇水平显着较低(P <.01)(DM中位数为0.188 [范围,0.092至0.313],CRF为0.088 [范围,0.031至0.140])。在DM高血压患者中发现可的松/皮质醇的双峰分布代表了比率为0.2时的高比率组和低比率组。肾功能,糖尿病持续时间和并发症在高比率组和低比率组之间有所不同。与比率较大的组相比,低比率组(<0.2)的11beta-HSD活性较低,血液中的尿素氮(BUN)水平升高,并且患有肾病,神经病,视网膜病和DM持续时间延长大于0.2。数据表明,血清可的松/皮质醇比值反映了11beta-HSD活性的变化,并且是依赖肾功能的。这是评估在DM和CRF患者中观察到的糖皮质激素过多高血压的可能标志物。 W.B.版权所有2001桑德斯公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号